Quest Diagnostics Inc Segment Expenditure Addition To Long Lived Assets
Quest Diagnostics Inc (DGX) reported Segment Expenditure Addition To Long Lived Assets of $527.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2026-02-26
- Quest Diagnostics Inc segment expenditure addition to long lived assets for fiscal 2025 was $527.00M, a 24.00% increase from fiscal 2024.
- Quest Diagnostics Inc segment expenditure addition to long lived assets for fiscal 2024 was $425.00M, a 4.17% increase from fiscal 2023.
- Quest Diagnostics Inc segment expenditure addition to long lived assets for fiscal 2023 was $408.00M, a 0.99% increase from fiscal 2022.
- Quest Diagnostics Inc segment expenditure addition to long lived assets for fiscal 2022 was $404.00M, a 0.25% increase from fiscal 2021.
| Period end | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|
| 2025-12-31 | $527.00M 10-K · filed 2026-02-26 |
| 2024-12-31 | $425.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | $408.00M 10-K · filed 2026-02-26 |
| 2022-12-31 | $404.00M 10-K · filed 2025-02-20 |
| 2021-12-31 | $403.00M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |